Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA, and Turkish Lymphoma Group.

Auteurs

Martínez C, Khvedelidze I, Fekom M, Deau Fischer B, Marouf A, Ghesquières H, Fornecker LM, Merli F, Stefani PM, Massaro F, Botto B, Ferhanoğlu B, Akay OM, Özbalak M, Espeso de Haro M, Romero S, Galimard JE, Glass B, Bazarbachi A, Sureda A

  • Date de publication

    April 2025

  • Type

    Article

  • Tijdschrift

    Bone Marrow Transplant

  • Naam van de onderzoeker

    MASSARO FULVIO

  • Hôpital

    Institut Jules Bordet

  • Dienst

    Hématologie

  • PMID

    40234724

  • DOI

    10.1038/s41409-025-02568-4